Lilly’s Cassell joins PhRMA bioterror team
Executive Summary
Lilly VP-Scientific Affairs Gail Cassell, PhD, joins the Pharmaceutical Research & Manufacturers of America on "part-time basis to work on the industry's biomedical preparedness issues." Cassell will "help to develop a long-term strategy for research on infectious diseases"...
You may also be interested in...
HHS Bioterror Research Oversight Preserved By Commerce Cmte. DHS Plan
HHS would retain authority over drug research related to bioterrorism under the House Energy & Commerce Committee mark of the "Homeland Security Act" (HR 5005) completed July 11
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.